Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Linifanib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-10-21

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT01225302

Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy

Phase 3

Conditions: Gastric Cancer

Interventions: Drug: Paclitaxel
Drug: Irinotecan

First Posted Date: 2010-10-20

Last Posted Date: 2010-10-20

Lead Sponsor: Korean Cancer Study Group

Target Recruit Count: 518

Registration Number: NCT01224652

Locations: 🇰🇷
Yonsei University Gangnam Severance Hospital, Seoul, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Phase 2

Terminated

Conditions: Neoplasms, Breast

Interventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A
Drug: Placebo
Drug: Aromatase inhibitor
Drug: Carboplatin AUC
Drug: 5-Fluorouracil
Drug: Docetaxel
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Epirubicin
Drug: Paclitaxel
Drug: Trastuzumab

First Posted Date: 2010-10-13

Last Posted Date: 2021-05-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 66

Registration Number: NCT01220128

Locations: 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

Phase 1

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: carboplatin
Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2010-10-13

Last Posted Date: 2018-02-08

Lead Sponsor: Ritu Salani

Target Recruit Count: 9

Registration Number: NCT01219777

Locations: 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Phase 1

Conditions: Primary Peritoneal Cancer
Fallopian Tube Cancer
No Prior Chemotherapy
Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2010-10-13

Last Posted Date: 2016-10-14

Lead Sponsor: David O'Malley

Target Recruit Count: 9

Registration Number: NCT01220154

Locations: 🇺🇸
OSU Gyn Oncology at Mill Run, Hilliard, Ohio, United States

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Phase 2

Completed

Conditions: Adenocarcinoma of the Lung

Interventions: Biological: Farletuzumab
Other: Placebo
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2010-10-11

Last Posted Date: 2020-08-20

Lead Sponsor: Morphotek

Target Recruit Count: 130

Registration Number: NCT01218516

Locations: 🇺🇸
Clinical Trials and Research Associates, Inc., Montebello, California, United States
🇺🇸
Medical Specialists of the Palm Beaches, Deerfield Beach, Florida, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 90 locations

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Phase 2

Terminated

Conditions: Bladder Carcinoma
Transitional Cell Carcinoma
Urothelial Carcinoma

Interventions: Drug: Everolimus
Drug: Paclitaxel

First Posted Date: 2010-10-06

Last Posted Date: 2023-11-24

Lead Sponsor: Matthew Galsky

Target Recruit Count: 36

Registration Number: NCT01215136

Locations: 🇺🇸
Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States
🇺🇸
Metro Health Cancer Care, Wyoming, Michigan, United States
🇺🇸
Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center, New York, New York, United States

and more 8 locations

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Phase 1

Completed

Conditions: Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,
Primary Peritoneal Cancer or Endometrial Cancer
Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer

Interventions: Drug: MM-121
Drug: Paclitaxel

First Posted Date: 2010-09-27

Last Posted Date: 2016-09-08

Lead Sponsor: Merrimack Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT01209195

Locations: 🇺🇸
Cancer Care Associates of Fresno, Fresno, California, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations